Jiangsu Nanfang Medical Co., Ltd. (603880.SS)
CNY 5.01
(4.16%)
CNY 5.01
(4.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 803.1 Million CNY | -3.91% |
| 2022 | 835.75 Million CNY | 44.02% |
| 2021 | 580.29 Million CNY | 56.06% |
| 2020 | 371.84 Million CNY | 23.09% |
| 2019 | 302.07 Million CNY | 5.7% |
| 2018 | 285.77 Million CNY | 0.13% |
| 2017 | 285.39 Million CNY | 9.82% |
| 2016 | 259.86 Million CNY | 3.59% |
| 2015 | 250.85 Million CNY | 10.95% |
| 2014 | 226.1 Million CNY | 10.41% |
| 2013 | 204.77 Million CNY | -20.75% |
| 2012 | 258.4 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 850.5 Million CNY | 8.42% |
| 2024 Q1 | 784.45 Million CNY | -2.32% |
| 2024 Q3 | 786.99 Million CNY | -7.47% |
| 2023 FY | 803.1 Million CNY | -3.91% |
| 2023 Q1 | 856.04 Million CNY | 2.43% |
| 2023 Q3 | 845.9 Million CNY | 8.56% |
| 2023 Q4 | 803.1 Million CNY | -5.06% |
| 2023 Q2 | 779.17 Million CNY | -8.98% |
| 2022 Q3 | 821.93 Million CNY | 14.84% |
| 2022 Q2 | 715.73 Million CNY | 6.16% |
| 2022 Q1 | 674.22 Million CNY | 16.19% |
| 2022 FY | 835.75 Million CNY | 44.02% |
| 2022 Q4 | 835.75 Million CNY | 1.68% |
| 2021 Q3 | 567.05 Million CNY | 7.73% |
| 2021 Q1 | 412.24 Million CNY | 10.87% |
| 2021 Q2 | 526.35 Million CNY | 27.68% |
| 2021 FY | 580.29 Million CNY | 56.06% |
| 2021 Q4 | 580.29 Million CNY | 2.33% |
| 2020 Q2 | 444.43 Million CNY | 38.54% |
| 2020 Q3 | 440.64 Million CNY | -0.85% |
| 2020 Q4 | 371.84 Million CNY | -15.61% |
| 2020 FY | 371.84 Million CNY | 23.09% |
| 2020 Q1 | 320.81 Million CNY | 6.2% |
| 2019 Q4 | 302.07 Million CNY | 33.19% |
| 2019 Q2 | 269.16 Million CNY | -4.73% |
| 2019 Q1 | 282.51 Million CNY | -1.14% |
| 2019 FY | 302.07 Million CNY | 5.7% |
| 2019 Q3 | 226.8 Million CNY | -15.74% |
| 2018 Q3 | 268.59 Million CNY | -4.79% |
| 2018 FY | 285.77 Million CNY | 0.13% |
| 2018 Q4 | 285.77 Million CNY | 6.4% |
| 2018 Q2 | 282.11 Million CNY | 12.59% |
| 2018 Q1 | 250.57 Million CNY | -12.2% |
| 2017 FY | 285.39 Million CNY | 9.82% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | 290.5 Million CNY | 0.0% |
| 2017 Q3 | 267.25 Million CNY | -8.0% |
| 2017 Q4 | 285.39 Million CNY | 6.79% |
| 2016 Q4 | 259.86 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 259.86 Million CNY | 3.59% |
| 2015 Q4 | 250.85 Million CNY | 0.0% |
| 2015 Q2 | 219.85 Million CNY | 0.0% |
| 2015 FY | 250.85 Million CNY | 10.95% |
| 2014 FY | 226.1 Million CNY | 10.41% |
| 2013 FY | 204.77 Million CNY | -20.75% |
| 2012 FY | 258.4 Million CNY | 0.0% |